ADXS - アドバクシス (Advaxis Inc.) アドバクシス

 ADXSのチャート


 ADXSの企業情報

symbol ADXS
会社名 Advaxis Inc (アドバクシス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アドバキシス(Advaxis Inc.)はリステリア・モノサイトゲネス(Lm)-リステリオリシン O(LLO)癌免疫療法の発見・開発・商業化に従事する臨床段階のバイオ技術会社である。これらの免疫療法は、抗原/アジュバント融合タンパク質を分泌する生きた弱毒化Lmバイオエンジニアリングを利用するプラットフォーム技術に基づいている。これらのLm-LLO株は、抗腫瘍T細胞免疫を刺激し、複数のアジュバントの等価物で免疫系を刺激・活性化するために、抗原提示細胞にアクセスして誘導すると同時に複数の機能を単一の免疫療法に統合し、同時にT細胞が腫瘍を排除することを可能にするために腫瘍微小環境における腫瘍保護を低下させる。Axalimogene filolisbacは、ヒトパピローマウイルス関連癌の治療用のリードLm-LLO免疫療法製品候補である。ADXS-PSAは、前立腺癌に関連する前立腺特異抗原(PSA)を標的とするLm-LLO免疫療法製品候補である。   アドバクシスは米国のバイオテクノロジ―企業。がんおよび感染症のための免疫療法の開発に従事。開発中の医薬品は、子宮頸がん、頭頸部がん、肛門がんの治療薬「ADXS-HPV」、前立腺がん向け「ADXS-PSA」、乳がん、胃がんや、ヒトにおける他のがんおよび犬の骨肉腫などのHER2過剰発現がんの治療薬「ADXS-cHER2」の開発を手掛ける。   Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.
本社所在地 305 College Road East Princeton NJ 08540 USA
代表者氏名 David Sidransky デビッド・シドランスキー
代表者役職名 Independent chairman of the Board
電話番号 +1 732-545-1590
設立年月日 31929
市場名 NASDAQ National Market System
ipoyear ―年
従業員数
url www.advaxis.com
nasdaq_url https://www.nasdaq.com/symbol/adxs
adr_tso
EBITDA EBITDA(百万ドル) -74.67294
終値(lastsale) 0.792
時価総額(marketcap) 55040158.008
時価総額 時価総額(百万ドル) 58.15208
売上高 売上高(百万ドル) 6.69732
企業価値(EV) 企業価値(EV)(百万ドル) 18.71808
当期純利益 当期純利益(百万ドル) -71.17769
決算概要 決算概要 BRIEF: For the nine months ended 31 July 2018 Advaxis Inc. revenues decreased 52% to $4.9M. Net loss decreased 32% to $47.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General and administrative decrease of 79% to $3.6M (expense) Research and Development Expenses decrease of 17% to $36.1M (expense) Other decrease of 31% to $10.9M (expense).

 ADXSのテクニカル分析


 ADXSのニュース

   Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update  2019/12/20 13:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announces its financial results for the fiscal year ended October 31, 2019 and provides a business update. Fiscal Year 2019 and Recent Key Accomplishments Completed enrollment in the first and second dose levels in Part A of the ongoing Phase 1/2 trial evaluating ADXS-503, the Company’s ADXS-HOT drug candidate in
   Advaxis to Present at 12th Annual LD Micro Main Event Investor Conference  2019/12/04 13:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer will present at the upcoming LD Micro Main Event Investor Conference being held from December 10-12, 2019 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Presentation Information: Date: Tuesday, December 10, 2019 Time:
   Advaxis Announces Submission of IND Application for ADXS-HOT Drug Candidate for Prostate Cancer  2019/12/03 13:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical study of ADXS-504, the Company’s ADXS-HOT drug candidate for prostate cancer. “We are pleased to announce continued clinical progress of our ADXS-HOT p
   The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J  2019/09/26 11:54:44 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 25.) Coherus Biosciences Inc (NASDAQ: CHRS ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 25.) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Advaxis, Inc. (NASDAQ: ADXS ) AnaptysBio Inc (NASDAQ: ANAB ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) AzurRx BioPharma Inc (NASDAQ: AZRX ) ( announced lackadaisical efficacy data for pancreatic insufficiency drug) BridgeBio Pharma Inc (NASDAQ: BBIO ) Calithera Biosciences Inc (NASDAQ: CALA ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Exagen Inc (NASDAQ: XGN ) (IPOed on Sep. 16) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Myovant Sciences Ltd (NYSE: MYOV ) Neon Therapeutics Inc (NASDAQ: NTGN ) Novelion Therapeutics Inc (NASDAQ: NVLN ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics Inc (NASDAQ: ONTX ) PDS Biotechnology Corp (NASDAQ: PDSB ) Plus Therapeutics Inc (NASDAQ: PSTV ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Sophiris Bio Inc (NASDAQ: SPHS ) Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Tocagen Inc (NASDAQ: TOCA ) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) Urogen Pharma Ltd (NASDAQ: URGN ) Vaxart Inc (NASDAQ: VXRT ) (announced positive topline results for an early-stage …
   The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug  2019/09/25 11:13:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 24) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Celgene Corporation (NASDAQ: CELG ) Natera Inc (NASDAQ: NTRA ) Sanofi SA (NASDAQ: SNY ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL )(announced positive results for the pediatric Phase 3 trial of dasiglucagon for severe hypoglycemia in diabetes) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 24) Aduro BioTech Inc (NASDAQ: ADRO ) Advaxis, Inc. (NASDAQ: ADXS ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) AnaptysBio Inc (NASDAQ: ANAB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) Clovis Oncology Inc (NASDAQ: CLVS ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Endologix, Inc. (NASDAQ: ELGX ) Erytech Pharma SA (NASDAQ: ERYP ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Fulcrum Therapeutics Inc (NASDAQ: FULC Innoviva Inc (NASDAQ: INVA ) Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Myovant Sciences Ltd (NYSE: MYOV ) Neon Therapeutics Inc (NASDAQ: NTGN ) Onconova Therapeutics Inc (NASDAQ: ONTX ) ProQR Therapeutics NV (NASDAQ: PRQR ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) (priced its IPO on Sept. 13) Seelos Therapeutics Inc (NASDAQ: …
   Microcaps mostly among midday movers  2019-04-03
Gainers: Ocean Power Technologies (NASDAQ: OPTT ) +176% . Netshoes (Cayman) (NYSE: NETS ) +23% . Evogene (NASDAQ: EVGN ) +22% . Zynerba Pharmaceuticals (NASDAQ: ZYNE ) +21% . DMC Global (NASDAQ: BOOM ) +19% . Fuel Tech (NASDAQ: FTEK ) +18% . VivoPower International (NASDAQ: VVP…
   GME and ADXS among premarket losers  2019-04-03
Fusion Connect (NASDAQ: FSNN ) -82% as audit problems prompt Chapter 11 analyst warning. More news on: Fusion Connect, Inc., Advaxis, Inc., AVEO Pharmaceuticals, Inc., Stocks on the move, Read more …
   Advaxis down 26% on pricing stock offering  2019-04-03
Advaxis (NASDAQ: ADXS ) prices its public offering of 2.5M common stock at a price of $4.00/share, for gross proceeds of ~ $10M. More news on: Advaxis, Inc., Healthcare stocks news, Stocks on the move, Read more …
   Advaxis Announces Pricing of Its Public Offering of Common Stock  2019-04-03 Business Wire
Advaxis, Inc. (Nasdaq: ADXS) (the Company) , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アドバクシス ADXS Advaxis Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)